Returning guest Dr. Laurence Albiges discusses novel combos in refractory RCC and gives an update on COSMIC-313, which analyzed cabozantinib in combination with nivolumab and ipilimumab.
Returning guest Dr. Laurence Albiges discusses novel combos in refractory RCC and gives an update on COSMIC-313, which analyzed cabozantinib in combination with nivolumab and ipilimumab.